197 related articles for article (PubMed ID: 23384673)
21. Efficacy of tyrosine kinase inhibitors in routine clinical practice: epidermal growth factor mutations and their implications.
Ovcaricek T; Cufer T; Kern I; Sodja E; Sadikov A
J Cancer Res Ther; 2013; 9(2):261-6. PubMed ID: 23771370
[TBL] [Abstract][Full Text] [Related]
22. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer.
Wu JY; Yu CJ; Shih JY; Yang CH; Yang PC
Lung Cancer; 2010 Mar; 67(3):348-54. PubMed ID: 19473721
[TBL] [Abstract][Full Text] [Related]
23. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.
Hata A; Katakami N; Yoshioka H; Takeshita J; Tanaka K; Nanjo S; Fujita S; Kaji R; Imai Y; Monden K; Matsumoto T; Nagata K; Otsuka K; Tachikawa R; Tomii K; Kunimasa K; Iwasaku M; Nishiyama A; Ishida T; Nishimura Y
Cancer; 2013 Dec; 119(24):4325-32. PubMed ID: 24105277
[TBL] [Abstract][Full Text] [Related]
24. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
Chang JW; Liu HP; Hsieh MH; Fang YF; Hsieh MS; Hsieh JJ; Chiu YT; Tsai HY; Chen YH; Chen YT; Hsu HY; Chen YT; Tsai SF; Chen YR; Hsi BL; Huang SF
Lung Cancer; 2008 Sep; 61(3):328-39. PubMed ID: 18304690
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery.
Ahn HK; Choi YL; Han JH; Ahn YC; Kim K; Kim J; Shim YM; Um SW; Kim H; Kwon OJ; Sun JM; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2013 Mar; 79(3):300-6. PubMed ID: 23261144
[TBL] [Abstract][Full Text] [Related]
26. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.
Yang JJ; Chen HJ; Yan HH; Zhang XC; Zhou Q; Su J; Wang Z; Xu CR; Huang YS; Wang BC; Yang XN; Zhong WZ; Nie Q; Liao RQ; Jiang BY; Dong S; Wu YL
Lung Cancer; 2013 Jan; 79(1):33-9. PubMed ID: 23079155
[TBL] [Abstract][Full Text] [Related]
27. Association between EGFR-TKI resistance and efficacy of radiotherapy for brain metastases from EGFR-mutant lung adenocarcinoma.
Hirata H; Nakamura K; Kunitake N; Shioyama Y; Sasaki T; Ohga S; Nonoshita T; Yoshitake T; Asai K; Inoue K; Nagashima A; Ono M; Honda H
Anticancer Res; 2013 Apr; 33(4):1649-55. PubMed ID: 23564810
[TBL] [Abstract][Full Text] [Related]
28. Identification of α1-antitrypsin as a potential prognostic biomarker for advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors by proteomic analysis.
Zhao W; Yang Z; Liu X; Tian Q; Lv Y; Liang Y; Li C; Gao X; Chen L
J Int Med Res; 2013 Jun; 41(3):573-83. PubMed ID: 23613495
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer.
Masago K; Fujita S; Togashi Y; Kim YH; Hatachi Y; Fukuhara A; Nagai H; Irisa K; Sakamori Y; Mio T; Mishima M
Oncol Rep; 2011 Oct; 26(4):795-803. PubMed ID: 21805046
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.
Cho SH; Park LC; Ji JH; Park S; Hwang DW; Lee JY; Choi YL; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ
Cancer Chemother Pharmacol; 2012 Aug; 70(2):315-20. PubMed ID: 22760226
[TBL] [Abstract][Full Text] [Related]
31. Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation.
Li Y; Wang Y; Niu K; Chen X; Xia L; Lu D; Kong R; Chen Z; Duan Y; Sun J
Oncotarget; 2016 Oct; 7(43):70535-70545. PubMed ID: 27655708
[TBL] [Abstract][Full Text] [Related]
32. Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer.
Ikeda T; Nakamura Y; Yamaguchi H; Tomonaga N; Doi S; Nakatomi K; Iida T; Motoshima K; Mizoguchi K; Nagayasu T; Tsukamoto K; Kohno S
Clin Lung Cancer; 2012 Sep; 13(5):369-74. PubMed ID: 22410386
[TBL] [Abstract][Full Text] [Related]
33. Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study.
Skinner KE; Fernandes AW; Walker MS; Pavilack M; VanderWalde A
J Med Econ; 2018 Feb; 21(2):192-200. PubMed ID: 29041833
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.
Spaans JN; Goss GD
Curr Opin Oncol; 2015 Mar; 27(2):102-7. PubMed ID: 25611026
[TBL] [Abstract][Full Text] [Related]
35. Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing.
Yeo CD; Kim JW; Kim KH; Ha JH; Rhee CK; Kim SJ; Kim YK; Park CK; Lee SH; Park MS; Yim HW
Lung Cancer; 2013 Aug; 81(2):207-12. PubMed ID: 23726527
[TBL] [Abstract][Full Text] [Related]
36. CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives.
Berger LA; Riesenberg H; Bokemeyer C; Atanackovic D
Lung Cancer; 2013 Jun; 80(3):242-8. PubMed ID: 23453646
[TBL] [Abstract][Full Text] [Related]
37. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
Kuiper JL; Hendriks LE; van der Wekken AJ; de Langen AJ; Bahce I; Thunnissen E; Heideman DA; Berk Y; Buijs EJ; Speel EJ; Krouwels FH; Smit HJ; Groen HJ; Dingemans AM; Smit EF
Lung Cancer; 2015 Sep; 89(3):255-61. PubMed ID: 26117231
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor receptor mutation study for 5 years, in a population of patients with non-small cell lung cancer.
Castro AS; Parente B; Gonçalves I; Antunes A; Barroso A; Conde S; Neves S; Machado JC
Rev Port Pneumol; 2013; 19(1):7-12. PubMed ID: 23265235
[TBL] [Abstract][Full Text] [Related]
39. Impact of smoking status on EGFR-TKI efficacy for advanced non-small-cell lung cancer in EGFR mutants: a meta-analysis.
Zhang Y; Kang S; Fang W; Hong S; Liang W; Yan Y; Qin T; Tang Y; Sheng J; Zhang L
Clin Lung Cancer; 2015 Mar; 16(2):144-151.e1. PubMed ID: 25454007
[TBL] [Abstract][Full Text] [Related]
40. Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient.
Pircher A; Manzl C; Fiegl M; Popper H; Pirker R; Hilbe W
Lung Cancer; 2014 Mar; 83(3):408-10. PubMed ID: 24412619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
